Is Indrapr.Medical overvalued or undervalued?

As of 18 November 2025, the valuation grade for Indrapr.Medical has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued. Key ratios include a PE ratio of 27.31, an EV to EBITDA of 16.83, and a PEG ratio of 1.50.
In comparison to its peers, Indrapr.Medical's valuation appears moderate, especially when compared to Max Healthcare, which is very expensive with a PE of 77.03, and Apollo Hospitals, which is attractive with a PE of 63.51. Notably, Indrapr.Medical has outperformed the Sensex over the past year with a return of 26.65% compared to the Sensex's 9.48%, reflecting its strong performance despite the recent grade change.